Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Payables (2018 - 2025)

Black Diamond Therapeutics (BDTX) has disclosed Payables for 3 consecutive years, with $4.9 million as the latest value for Q3 2021.

  • For the quarter ending Q3 2021, Payables rose 65.72% year-over-year to $4.9 million, compared with a TTM value of $4.9 million through Sep 2021, up 65.72%, and an annual FY2020 reading of $2.5 million, up 29.23% over the prior year.
  • Payables was $4.9 million for Q3 2021 at Black Diamond Therapeutics, down from $5.0 million in the prior quarter.
  • Across five years, Payables topped out at $5.0 million in Q2 2021 and bottomed at $45000.0 in Q2 2020.
  • Average Payables over 3 years is $3.2 million, with a median of $3.4 million recorded in 2020.
  • Peak annual rise in Payables hit 11077.78% in 2021, while the deepest fall reached 21.54% in 2021.
  • Year by year, Payables stood at $2.0 million in 2019, then increased by 29.23% to $2.5 million in 2020, then surged by 91.45% to $4.9 million in 2021.
  • Business Quant data shows Payables for BDTX at $4.9 million in Q3 2021, $5.0 million in Q2 2021, and $4.6 million in Q1 2021.